Background Establishing cardiovascular safety of new therapies for type 2 diabetes is
important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 …

Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week
subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for …

This guideline update reflects substantial advances in the epidemiology, determinants,
pathophysiology, assessment, prevention and treatment of obesity, and shifts the focus of obesity …

Background Obesity is a major public health issue, and new pharmaceuticals for weight
management are needed. Therefore, we evaluated the efficacy and safety of the glucagon-like …

Background Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a
long-acting amylin analogue under investigation for weight management. We assessed the …

Background Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin
analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin (HbA …

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical
practice for the treatment of type 2 diabetes, and are approved and recommended for weight …

Background Once-daily oral semaglutide is an effective type 2 diabetes treatment. We aimed
to investigate a new formulation of oral semaglutide at higher investigational doses versus …

Our aim was to examine the effects of GLP-1 and PYY 3–36 , separately and in combination,
on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, …

OBJECTIVE Most individuals with type 2 diabetes also have obesity, and treatment with
some diabetes medications, including insulin, can cause further weight gain. No approved …